Das Manoja Kumar, Mahapatra Ashoka, Pathi Basanti, Panigrahy Rajashree, Pattnaik Swetalona, Mishra Sudhansu Shekhar, Mahapatro Samarendra, Swain Priyabrat, Das Jayakrushna, Dixit Shikha, Sahoo Satya Narayan, Pillai Rakesh N
The INCLEN Trust International, New Delhi, India.
Department of Public Health, The INCLEN Trust International, New Delhi, India.
JMIR Res Protoc. 2020 Oct 30;9(10):e23241. doi: 10.2196/23241.
India has the largest burden of drug‑resistant organisms compared with other countries around the world, including multiresistant and extremely drug‑resistant tuberculosis and resistant Gram‑negative and Gram‑positive bacteria. Antibiotic resistant bacteria are found in all living hosts and in the environment and move between hosts and ecosystems. An intricate interplay of infections, exposure to antibiotics, and disinfectants at individual and community levels among humans, animals, birds, and fishes triggers evolution and spread of resistance. The One Health framework proposes addressing antibiotic resistance as a complex multidisciplinary problem. However, the evidence base in the Indian context is limited.
This multisectoral, trans-species surveillance project aims to document the infection and resistance patterns of 7 resistant-priority bacteria and the risk factors for resistance following the One Health framework and geospatial epidemiology.
This hospital- and community-based surveillance adopts a cross-sectional design with mixed methodology (quantitative, qualitative, and spatial) data collection. This study is being conducted at 6 microbiology laboratories and communities in Khurda district, Odisha, India. The laboratory surveillance collects data on bacteria isolates from different hosts and their resistance patterns. The hosts for infection surveillance include humans, animals (livestock, food chain, and pet animals), birds (poultry), and freshwater fishes (not crustaceans). For eligible patients, animals, birds and fishes, detailed data from their households or farms on health care seeking (for animals, birds and fishes, the illness, and care seeking of the caretakers), antibiotic use, disinfection practices, and neighborhood exposure to infection risks will be collected. Antibiotic prescription and use patterns at hospitals and clinics, and therapeutic and nontherapeutic antibiotic and disinfectant use in farms will also be collected. Interviews with key informants from animal breeding, agriculture, and food processing will explore the perceptions, attitudes, and practices related to antibiotic use. The data analysis will follow quantitative (descriptive and analytical), qualitative, and geospatial epidemiology principles.
The study was funded in May 2019 and approved by Institute Ethics Committees in March 2019. The data collection started in September 2019 and shall continue till March 2021. As of June 2020, data for 56 humans, 30 animals and birds, and fishes from 10 ponds have been collected. Data analysis is yet to be done.
This study will inform about the bacterial infection and resistance epidemiology among different hosts, the risk factors for infection, and resistance transmission. In addition, it will identify the potential triggers and levers for further exploration and action.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/23241.
与世界其他国家相比,印度耐药生物的负担最为沉重,其中包括多重耐药和极端耐药的结核病以及耐药革兰氏阴性菌和革兰氏阳性菌。抗生素耐药菌存在于所有生物宿主和环境中,并在宿主和生态系统之间传播。人类、动物、鸟类和鱼类在个体和社区层面上,感染、接触抗生素和消毒剂之间复杂的相互作用引发了耐药性的演变和传播。“同一健康”框架建议将抗生素耐药性作为一个复杂的多学科问题来解决。然而,印度背景下的证据基础有限。
这个多部门、跨物种监测项目旨在按照“同一健康”框架和地理空间流行病学记录7种耐药重点细菌的感染和耐药模式以及耐药风险因素。
这项基于医院和社区的监测采用横断面设计,并采用混合方法(定量、定性和空间)收集数据。本研究在印度奥里萨邦库尔达区的6个微生物实验室和社区开展。实验室监测收集来自不同宿主的细菌分离株及其耐药模式的数据。感染监测的宿主包括人类、动物(家畜、食物链动物和宠物)、鸟类(家禽)和淡水鱼(不包括甲壳类动物)。对于符合条件的患者、动物、鸟类和鱼类,将收集其家庭或养殖场关于就医情况(对于动物、鸟类和鱼类,是其疾病以及看护者的就医情况)、抗生素使用、消毒措施以及社区感染风险暴露的详细数据。还将收集医院和诊所的抗生素处方和使用模式,以及养殖场治疗性和非治疗性抗生素及消毒剂的使用情况。对动物养殖、农业和食品加工领域关键知情者的访谈将探讨与抗生素使用相关的认知、态度和做法。数据分析将遵循定量(描述性和分析性)、定性和地理空间流行病学原则。
该研究于2019年5月获得资助,并于2019年3月获得机构伦理委员会批准。数据收集于2019年9月开始,将持续至2021年3月。截至2020年6月,已收集了56名人类、30只动物和鸟类以及来自10个池塘的鱼类的数据。数据分析尚未进行。
本研究将提供有关不同宿主间细菌感染和耐药流行病学、感染风险因素以及耐药传播的信息。此外,它还将确定进一步探索和行动的潜在触发因素和杠杆。
国际注册报告识别码(IRRID):DERR1-10.2196/23241。